TrademarkDir
AP
DEAD

Serial Number

78570329

Owner

Actimis Pharmaceuticals, Inc.

Attorney

John Paul Oleksiuk

Filing Date

Feb 18, 2005

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

AP Trademark

Serial Number: 78570329 • Registration: 3636768

AP is a trademark filed by Actimis Pharmaceuticals, Inc. on February 18, 2005. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Actimis Pharmaceuticals, Inc. (3 trademarks)

10835 Road To The Cure
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

February 18, 2005

Registration Date

June 9, 2009

Published for Opposition

July 25, 2006

Cancellation Date

January 10, 2020

Goods & Services

Scientific research, technological and development services, namely, pharmaceutical research and pharmaceutical drug development services for applying proprietary chemical technologies and analysis to pharmaceutical drug discovery processes and research, identifying novel drug targets and biomarkers, selectively profiling drug candidates in biological samples, characterizing target activities of drug candidates and established drugs to understand the basis for their efficacy and toxicity, and monitoring clinical trials in the field of respiratory, anti-inflammatory and auto-immunity disorders; laboratory research in the field of respiratory, anti-inflammatory and auto-immunity disorders

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Jan 10, 2020 CAEX
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jun 9, 2018 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 26, 2016 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 26, 2016 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 26, 2016 APRE
TEAS SECTION 8 & 15 RECEIVED
Nov 18, 2015 E815
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 15, 2013 TCCA
REVIEW OF CORRESPONDENCE COMPLETE
Jan 12, 2010 CORV
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 11, 2010 APRE
PAPER RECEIVED
Jul 21, 2009 MAIL
REGISTERED-PRINCIPAL REGISTER
Jun 9, 2009 R.PR
LAW OFFICE REGISTRATION REVIEW COMPLETED
May 6, 2009 REGV
ASSIGNED TO LIE
May 6, 2009 ALIE
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 6, 2009 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 20, 2009 SUPC
SOU EXTENSION 5 GRANTED
Apr 20, 2009 EX5G
USE AMENDMENT FILED
Apr 16, 2009 IUAF
SOU EXTENSION 5 FILED
Apr 16, 2009 EXT5
SOU TEAS EXTENSION RECEIVED
Apr 16, 2009 EEXT
TEAS STATEMENT OF USE RECEIVED
Apr 16, 2009 EISU
SOU EXTENSION 4 GRANTED
Oct 17, 2008 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 15, 2008 AITU
SOU EXTENSION 4 FILED
Oct 14, 2008 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 14, 2008 EEXT
SOU EXTENSION 3 GRANTED
Apr 21, 2008 EX3G
SOU EXTENSION 3 FILED
Apr 11, 2008 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 11, 2008 EEXT
SOU EXTENSION 2 GRANTED
Oct 23, 2007 EX2G
SOU EXTENSION 2 FILED
Oct 14, 2007 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 14, 2007 EEXT
SOU EXTENSION 1 GRANTED
Jul 19, 2007 EX1G
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 31, 2007 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 31, 2007 COAR
SOU EXTENSION 1 FILED
Apr 9, 2007 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 9, 2007 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Oct 17, 2006 NOAM
PUBLISHED FOR OPPOSITION
Jul 25, 2006 PUBO
NOTICE OF PUBLICATION
Jul 5, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 7, 2006 PREV
ASSIGNED TO LIE
May 31, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 18, 2006 CNSA
AMENDMENT FROM APPLICANT ENTERED
Apr 20, 2006 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 5, 2006 CRFA
PAPER RECEIVED
Apr 5, 2006 MAIL
NON-FINAL ACTION E-MAILED
Oct 3, 2005 GNRT
NON-FINAL ACTION WRITTEN
Oct 3, 2005 CNRT
ASSIGNED TO EXAMINER
Sep 15, 2005 DOCK
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 5, 2005 COAR
NEW APPLICATION ENTERED
Mar 2, 2005 NWAP

Related Trademarks

More from this Owner

AP ACTIMIS PHARMACEUTICALS logo

AP ACTIMIS PHARMACEUTICALS

AP ACTIMIS PHARMACEUTICALS logo

AP ACTIMIS PHARMACEUTICALS

AP ACTIMIS PHARMACEUTICALS logo

AP ACTIMIS PHARMACEUTICALS

ACTIMIS

ACTIMIS

ACTIMIS

ACTIMIS

ACTIMIS

ACTIMIS